- Oct 14 | Bio-IT World | A San Francisco-based startup is using robotic automation to “industrialize” the organoid and scale up use of the next-generation human in vitro models in drug discovery experiments for brain diseases. The plan is to use these intact systems, inclusive of microglia as well as neurons, to go after genetically complicated diseases and apply machine learning techniques to find connections between the multi-phenotypic data that gets generated. More
- Oct 13 | Bio-IT World | Bio-IT World is accepting entries for the 2022 Innovative Practices Awards competition. The deadline for entry is March 1, 2022, and the $300 application fee will be waived for entrants who meet the early deadline of January 14, 2022. More
- Oct 12 | Bio-IT World | Exosomal trafficking from fat to heart cells may help explain the “obesity paradox,” the baffling observation that packing extra pounds can have a beneficial, if short-term, protective effect for patients with heart disease. The cargo being delivered are oxidatively damaged mitochondrial particles that appear to prompt the heart to produce a flood of protective antioxidant molecules, better preparing it to cope with insults that later come along—such as a heart attack. More
- Oct 11 | Bio-IT World | CRISPR unicorn, pan-coronavirus vaccine research, chemical and biological weapons protection for warfighters, new methods for live cell research, seed round for a new drug discovery platform, and more. More
- Oct 07 | Bio-IT World | New leadership at JAX, Illumina expands into Latin America, PacBio partners with The European Reference Genome Atlas, UK Biobank’s Research Analysis Platform is now live, and BC Platforms seeks to build the largest integrated clinical and genomics data biobank in Africa. Plus: new products from MemVerge, Quantum, Pure Storage, Sensyne Health, and more. More
- Oct 06 | Bio-IT World | The Pistoia Alliance surveyed life sciences professionals this summer to gauge their understanding of quantum computing. They found that almost half classify their understanding of quantum computing (QC) technology at beginner level only. These results, the Alliance argues, show that despite significant noise around the potential of QC, few life science organizations or individuals are yet able to apply the technology. More
Trends from the Trenches 2021: Where Bio-IT Stands on Digital Transformation, Data Transformation, AI/MLOct 05 | Bio-IT World | Chris Dagdigian wasn’t the only speaker at the Bio-IT World Conference & Expo Trends from the Trenches session. He also welcomed Adam Kraut, Karl Gutwin, and Fernanda Foertter—all BioTeam or former BioTeam consultants—to report on trends in digital transformation, data transformation, and AI/ML. More
- Oct 04 | Bio-IT World | Cognitive search—and the intelligence and analytics that go with it—could well be the key element for optimizing innovation and improving the efficiency of research, clinical trials, and regulatory processes. More
- Sep 29 | Bio-IT World | At the beginning of September, the National Institutes of Health launched the Impact of Genomic Variation on Function (IGVF) consortium, a new initiative of NIH’s National Human Genome Research Institute (NHGRI). Now, NHGRI has named the first 25 awards across 30 U.S. research sites totaling approximately $185 million over five years. More
Trends in the Trenches 2021: Chris Dagdigian on Security Vaporware, Egnyte, and the Data Management CultureSep 28 | Bio-IT World | At this year’s Trends from the Trenches plenary presentation, Chris Dagdigian brought an overview of the trends and a warning of the technology pitfalls facing the Bio-IT community. He continued to beat his drum on a few cultural issues Bio-IT still needs to address, and he alerted the community to what’s new and notable. More
- Oct 15 | More
- Oct 15 | More
CluePoints partners with ZS to provide best-in-class RBQM expertise and technology, increasing clinical trial efficiency and improving patient outcomesOct 15 | CluePoints, the premier provider of risk-based quality management (RBQM) and data oversight software for clinical trials, has partnered with ZS, a global professional services firm with technology and analytics expertise in biopharma, to offer innovative capabilities in portfolio-level performance oversight. The new partnership pairs a best-in-breed solutions company focused on study-level risk-based management with a pharmaceutical and biotech solutions provider with advanced capabilities in portfolio-level quality and operational oversight. More
- Oct 15 | More
Certara’s Simcyp™ COVID-19 Vaccine Model Named Finalist in Both the 2021 Citeline Awards and R&D 100 AwardsOct 15 | Certara’s Simcyp COVID-19 Vaccine Model uses biosimulation to improve decision-making and help optimize dosing regimens of COVID-19 vaccines. Certara calibrated its model using the structure of actual COVID-19 vaccines and validated it by replicating the published clinical data. The model, which is incorporated in Certara’s Vaccine Simulator™, addresses important questions such as differences in response with age and ethnicity, optimal timing between doses and expected duration of antibody response. More
- Oct 15 | More
- Aug 20 | Deep longitudinal, disease agnostic structured global dataset, covering over 4,000 indications will industrialize Sensyne’s life sciences activities More
Cisco fixes vulnerability that allowed criminals to remotely execute arbitrary code and control a firewallAug 20 | Positive Technologies researchers discovered a vulnerability in Cisco Firepower Device Manager On-Box – a product designed to locally configure Cisco Firepower firewalls. Now patched, the flaw could allow attackers to gain full control over the device and its capabilities. That could include handing over to criminals the ability to filter traffic. Attackers could also shut down a firewall, or even access other internal resources within an enterprise, if they’re located on the same subnet. More
Biofourmis Earns FDA’s First-Ever Breakthrough Device Designation for a Novel Digital Therapeutic for Heart FailureAug 20 | Biofourmis completed a proof of concept study for its heart failure digital therapeutic BiovitalsHF that met its endpoint of number of patients at 50% of optimal therapy. As a result, FDA has granted the DTx the first-ever Breakthrough Designation for a heart failure digital therapy. More
Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and
data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!
Digital Therapeutics: Taking digital health to a new level
Benchling is the most widely-adopted life sciences R&D cloud. Accelerate, measure, and forecast R&D – from discovery through bioprocessing – all in one place. It’s a fully unified platform that centralizes and standardizes all R&D data, so you can spend less time fighting with legacy software, and more time reaching breakthrough discoveries.
Read more here!